Newborn screening instruments is predicted to grow at a rapid pace in coming years pertaining to an increase in awareness regarding neonatal diseases and continuous improvement in pediatric care in emerging economies. The goal of newborn screening instruments are used to detect diseases as early as possible in order to mitigate the most severe effects by prompt intervention. Screening is not a diagnosis for confirmation and needs further examinations. Owing to the high incidence of some endocrinopathies, metabolic errors and hearing loss, recommendations from certain developing countries prescribe newborn screening before discharge, which leads to severe morbidity if remembered later.
New ways of screening can help neonates live longer and healthy lives and prevent diseases from having symptoms and effects. In both the early diagnosis of conditions and in therapies, there are many advances that make neonatal screening a matter of considerable interest. Examples of promising therapies are enzyme replacement therapy and stem cell transplantation and many more. Recent human genome sequencing and large investments in genomics research have created strong hopes for the translation from laboratory to population health benefits of genetic and genomic information.
Europe accounts for noticeable market share in the global market. As an important public health programme, neonatal screening has been introduced in many European countries over the last 50 years. This implementation has resulted in varying approaches to the way the screening services have been set up, funded and regulated, based on the health care structure, available funding, state politics, participation from specialist associations, parent groups and the public.
Newborn screening has firmly established its place in the group of cost-efficient public health instruments through these improved performance characteristics. It has risen above the level of amateur-enthusiasm on a small scale and has moved into well-organized long-term national health care provisions in many countries.
Adroit Market Research study on the global market for newborn screening instruments offers a holistic view of the industry from 2020 to 2028 as forecast period, including factors such as market drivers, limitations, opportunities, threats and regulatory overview. The market has been analyzed from 2018 to 2028, with a base year estimate of 2019 and a projection from 2020 to 2028. The report covers the current status and potential characteristics of the market at both the global and the country level. Moreover, the report also assesses market competition with Porter's analysis of five strengths and places leading players on the basis of their product range, regional presence, strategic initiatives and overall sales. Prominent players in the global composite resin market have been analyzed in depth. Key vendors in the market include GE Healthcare, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Waters Corp, Trivitron Healthcare, PerkinElmer, and any among others.
Key Segments of the Global Newborn Screening Instruments Market
Product Overview, 2018-2028 (USD Million)
- Reagents & Assay Kits
Technology Overview, 2018-2028 (USD Million)
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assays
- DNA Assays
Test Overview, 2018-2028 (USD Million)
- Dry Blood Spot Test
- Critical Congenital Heart Disease (CCHD)
- Hearing Screen
Regional Overview, 2018-2028 (USD Million)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia-Pacific
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- South America
- Rest of South America